Biologic switching between interleukin 17A antagonists secukinumab and ixekizumab: a 12‐week, multicenter, retrospective study. (20th June 2018) - Georgakopoulos, J.R.; Phung, M.; Ighani, A.; Lam, K.; Yeung, J.